Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7685732 | 0.79 | USP2 (0.44) | HTTMEN1KMT2AUSP2BCHE | |
| SCHEMBL28915706 | 0.79 | USP2 (0.44) | HTTMEN1KMT2AUSP2BCHE | |
| SCHEMBL30842142 | 0.73 | TAAR1 (0.44) | HTTUSP2TAAR1KCNH2TSHR | |
| SCHEMBL28594881 | 0.73 | MEN1 (0.46) | HTTMEN1KMT2AUSP2BCHE | |
| SCHEMBL16796869 | 0.72 | BCHE (0.63) | HTTMEN1KMT2AUSP2BCHE | |
| SCHEMBL28573258 | 0.70 | KCNH2 (0.41) | USP2TAAR1ALDH1A1GAAGRM2 | |
| SCHEMBL28581918 | 0.69 | USP2 (0.51) | HTTMEN1KMT2AUSP2TAAR1 | |
| SCHEMBL28587695 | 0.69 | USP2 (0.51) | HTTMEN1KMT2AUSP2TAAR1 | |
| SCHEMBL28914856 | 0.69 | MEN1 (0.42) | HTTMEN1KMT2AUSP2TAAR1 | |
| SCHEMBL8810696 | 0.67 | BCHE (0.52) | MEN1KMT2AUSP2BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173747-B1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2011-12-21 | — | — | EP | claimed |
| US-20100216988-A1 | Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2010-08-26 | — | — | US | claimed |
| EP-2173747-B1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2011-12-21 | — | — | EP | disclosed |
| US-20100216988-A1 | Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2010-08-26 | — | — | US | disclosed |
| EP-2173747-A1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009000412-A1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI AVENTIS (FR) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216988-A1 | Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | AZI2, NIT2, NISCH | HTT 3742/4885MEN1 699/4885KMT2A 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.